Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin O. G. Nilsen OriginalPaper Pages: S5 - S9
Clinical relevance of intracellular and extracellular concentrations of macrolides C. Carbon OriginalPaper Pages: S10 - S14
Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice N. C. KaralusJ. E. GarrettC. J. Ryan OriginalPaper Pages: S15 - S20
Pharmacoeconomic evaluation of roxithromycin versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study W. G. ScottB. C. CooperH. M. Scott OriginalPaper Pages: S21 - S24
The overall safety of oral roxithromycin in paediatric clinical studies P. BéguéJ. Astruc OriginalPaper Pages: S25 - S27
Potential role of roxithromycin against theMycobacterium avium complex L. S. YoungL. E. BermudezC. B. Inderlied OriginalPaper Pages: S28 - S32
Prevention ofPneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients J. DurantF. HazimeP. Dellamonica OriginalPaper Pages: S33 - S38
Roxithromycin in the treatment of lyme disease-update and perspectives R. GasserI. WendelinW. Klein OriginalPaper Pages: S39 - S43
Helicobacter pylori: The place of the new macrolides in the eardication of the bacteria in peptic ulcer disease A. BuretteY. Glupczynski OriginalPaper Pages: S44 - S52